Surrogate Biomarkers

Yongming Qu ()
Additional contact information
Yongming Qu: Eli Lilly and Company, Lilly Corporate Center, Department of Biometrics

A chapter in Statistical Methods in Biomarker and Early Clinical Development, 2019, pp 39-52 from Springer

Abstract: Abstract Drug development is generally a long and costly process. The average cost of developing a new medicine that gains marketing approval is estimated at $2558 million, according to a new study by the Tufts Center for the Study of Drug Development. The most critical stages of drug development are phase 2 and 3 development. One major reason that the average drug development cost is so high is that there are many failures in later phase clinical development.

Date: 2019
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-030-31503-0_3

Ordering information: This item can be ordered from
http://www.springer.com/9783030315030

DOI: 10.1007/978-3-030-31503-0_3

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().